Clinical trial
An Efficacy and Safety Study of Galantamine for the Treatment of Patients With…
NCT00301574 · Janssen Pharmaceutical K.K., Industry · Completed
Key facts
| NCT number | NCT00301574 |
|---|---|
| Title | An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease. |
| Official title | Placebo-Controlled, Double-Blind Study of Galantamine (R113675) in the Treatment of Alzheimer's Disease. |
| Lead sponsor | Janssen Pharmaceutical K.K., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimer Disease |
| Intervention type | Drug |
| Interventions | galantamine |
| Enrollment | 398 |
| Start date | Apr 1, 2001 |
| Completion | Feb 1, 2004 |
| First posted | Mar 13, 2006 |
| Last update posted | May 17, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: